Rafarma Pharmaceuticals, Inc. (OTC: RAFA) has announced new international cooperation. Representatives of the company visited Turkey and, on April 24, signed a Protocol on Interests and Cooperation with Istem Medikal, the leading manufacturer and distributor of urological medical equipment and disposable products.
Under the protocol, companies have agreed on the mutual production and promotion of each other products in target markets. Rafarma Pharmaceuticals will provide medicine contract production for Mexico, Kazakhstan, Russia, Uzbekistan, Kyrgyzstan and Colombia. Istem Medikal, in turn, takes on the responsibilities for the production of Rafarma Pharmaceuticals’ preparations for Syria, Iraq, Iran, Sudan and Israel.
The terms, volumes, product range, necessary documentation and other specific data and decisions will be discussed by the companies soon.
ABOUT ISTEM MEDIKAL:
Istem Medikal is the leading innovative, reliable and environment-friendly medical devices manufacturer and supplier in Turkey since 2007. Supported by the Turkish Ministry of Industry & Trade, the company strives to improve the quality of its products and to maintain self-development with increasing product variety groups every year. Istem Medikal’s vision is to accelerate the development of health sector doing the best that it can.
For more information, please visit https://istemmedikal.com/en/
ABOUT RAFARMA PHARMACEUTICALS:
Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging and many other fields at the moment.
For more information, please visit https://www.noyarp.com
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Source: Rafarma Pharmaceuticals, Inc.